Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers.
This study aimed to investigate whether endothelial cells are damaged and to evaluate fibrinolytic system function in patients with type 2 diabetes. For this proposal, plasma levels of von Willebrand factor (an endothelial marker of injury), homocysteine (an inductor of endothelial injury), D-dimer (a marker of coagulation cascade activation) and plasminogen activator inhibitor-1 (a fibrinolysis marker) were measured in individuals with both type 2 diabetes and high blood pressure, with type 2 diabetes, with high blood pressure and in healthy control individuals. No significant differences among groups were observed for von Willebrand factor and homocysteine plasma levels. The type 2 diabetes and high blood pressure group presented a significant difference to the other groups for D-dimer and also presented high values for plasminogen activator inhibitor-1. The high blood pressure group and type 2 diabetes group presented separately higher values of plasminogen activator inhibitor-1 compared with the control group. High levels of D-dimer and plasminogen activator inhibitor-1 in patients with type 2 diabetes and high blood pressure with normoalbuminuria therefore indicate a state of hypercoagulability and hypofibrinolysis, despite no evident microvascular injury supported by normal levels of von Willebrand factor and homocysteine.
Soares
Anna Letícia
AL
Campus UFMG, Faculdade de Farmácia, Belo Horizonte, Minas Gerais, Brazil.
Sousa
Marinez de Oliveira
Mde O
Dusse
Luci Maria
LM
Fernandes
Ana Paula Salles Moura
AP
Lasmar
Marcelo Carvalho
MC
Novelli
Bethânia Alves
BA
Lages
Geralda de Fátima Guerra
Gde F
Carvalho
Maria das Graças
Md
D015415:Biomarkers / Q000097:blood; D048909:Diabetes Complications / Q000097:blood / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000473:pathology; D042783:Endothelial Cells / Q000378:metabolism / Q000473:pathology; D004730:Endothelium, Vascular / Q000293:injuries / Q000378:metabolism*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005342:Fibrinolysis; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D014841:von Willebrand Factor / Q000032:analysis*
D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; C036309:fibrin fragment D; D014841:von Willebrand Factor; D006710:Homocysteine